Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;26(9):576-83.
doi: 10.1016/j.nmd.2016.05.016. Epub 2016 May 27.

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy

Collaborators, Affiliations

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy

Eugenio Mercuri et al. Neuromuscul Disord. 2016 Sep.

Erratum in

Abstract

High variability in patients' changes in 6 minute walk distance (6MWD) over time has complicated clinical trials of treatment efficacy in Duchenne muscular dystrophy (DMD). We assessed whether boys with DMD could be grouped into classes that shared similar ambulatory function trajectories as measured by 6MWD. Ambulatory boys aged 5 years or older with genetically confirmed DMD who were enrolled in a natural history study at 11 care centers throughout Italy were included. For each boy, standardized assessments of 6MWD were available at annual intervals spanning 3 years. Trajectories of 6MWD vs. age and trajectories of 6MWD vs. time from enrollment were examined using latent class analysis. A total of 96 boys were included. At enrollment, the mean age was 8.3 years (mean 6MWD: 374 meters). After accounting for age, baseline 6MWD, and steroid use, four latent trajectory classes were identified as explaining 3-year 6MWD outcomes significantly better than a single average trajectory. Patient trajectories of 6MWD change from enrollment were categorized as having fast decline (n = 25), moderate decline (n = 19), stable function (n = 37), and improving function (n = 15) during the 3-year follow-up. After accounting for trajectory classes, the standard deviation of variation in 6MWD was reduced by approximately 40%. The natural history of ambulatory function in DMD may be composed of distinct trajectory classes. The extent to which trajectories are associated with novel and established prognostic factors warrants further study. Reducing unexplained variation in patient outcomes could help to further improve DMD clinical trial design and analysis.

Keywords: Ambulatory function; Duchenne muscular dystrophy; Latent class trajectory analysis; Natural history; Variability.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Individual patient trajectories of 6MWD vs. age. Each point represents a patient's 6MWD, with lines connecting annual assessments from the same individual patient.
Fig. 2
Fig. 2
Predicted and observed trajectories of 6MWD vs. age. Solid black lines represent the predicted mean 6MWD trajectory in each class; gray lines represent the individual patient trajectories assigned to each class.
Fig. 3
Fig. 3
Changes in 6MWD vs. time from enrollment. The solid black line represents the mean change in 6MWD from enrollment at each of the 3 follow-up years; error bars represent ±one standard deviation. Gray lines represent individual patient trajectories. Solid black points represent visits with loss of ambulation (defined as 6MWD = 0 meter).
Fig. 4
Fig. 4
Predicted and observed trajectories of 6MWD vs. time from enrollment. Solid colored lines represent the predicted mean 6MWD trajectory in each class; gray lines represent the individual patient trajectories assigned to each class. Solid black points represent visits with loss of ambulation (defined as 6MWD = 0 meter).

References

    1. Hoffman E.P., Brown R.H., Jr, Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–928. - PubMed
    1. Emery A.E.H., Muntoni F., Quinlivan R. Oxford monographs on medical genetics. 4th ed. Oxford University Press; Oxford: 2015. Duchenne muscular dystrophy. 308 p; ix.
    1. Ricotti V., Ridout D.A., Scott E. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84:698–705. - PubMed
    1. Pane M., Fanelli L., Mazzone E.S. Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscul Disord. 2015;25:749–753. - PMC - PubMed
    1. Mazzone E., Bianco F., Main M. Six minute walk test in type III spinal muscular atrophy: a 12 month longitudinal study. Neuromuscul Disord. 2013;23:624–628. - PubMed

Publication types